Compounded Retatrutide 10mg

Retatrutide Peptide

Also known as LY3437943 or NOP2Y096GV, is a synthetic peptide consisting of 39 amino acids. It functions as an agonist for three distinct endogenous peptides:

• Gastric inhibitory polypeptide (GIP)
• Glucagon-like peptide-1 (GLP-1)
• Glucagon (GCG)

The sequence of Retatrutide is primarily based on the GIP sequence but has been modified to target GLP-1 and GCG receptors, favoring GIP. It is also chemically enhanced with a fatty di-acid C20 moiety for improved stability (source).

Specifications

• Molecular Formula: C223H343F3N46O70
• Molecular Weight: 4731.55 g/mol
• Sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3

Research

General Research

Retatrutide activates GIP, GLP-1, and GCG receptors across various tissues, including the nervous system, gastric tract, liver, pancreas, and adipose tissue. These actions may regulate hunger, satiety signals, and hormone synthesis, influencing glucose metabolism and thermogenesis (Jakubowska et al., 2024).

With Adipose Tissue

Studies suggest that Retatrutide may enhance thermogenesis and leptin synthesis in fat cells through GLP-1 and GCG receptor activation (Conceição-Furber et al., 2022). Additional research indicates it could transform white fat into beige fat, boosting energy expenditure via pathways such as UCP1-mediated thermogenesis (Folli et al., 2023).

With Liver Cells

Retatrutide’s impact on GCG receptors in liver cells may promote lipid oxidation, mitochondrial biogenesis, and increased metabolic enzyme activity. These actions could reduce liver fat content and boost whole-body thermogenesis (Doggrell, 2023).

With the Central Nervous System

Activation of GLP-1 and GIP receptors in the brain may regulate hunger hormones such as NPY and AgRP while enhancing satiety signals (van Bloemendaal et al., 2014). This interaction could significantly influence energy balance and appetite (Samms et al., 2021).

With the Gastrointestinal Tract

By targeting GLP-1 and GCG receptors in the stomach, Retatrutide may delay gastric emptying and modulate gastric hormones like ghrelin and PYY 3-36 (Urva et al., 2023). These effects may contribute to improved satiety and reduced caloric intake.

With Pancreatic Cells

In pancreatic cells, Retatrutide may enhance insulin secretion by beta cells and suppress glucagon release by alpha cells, optimizing glucose regulation (Rosenstock et al., 2023). Experimental data suggest Retatrutide could lower HbA1c levels by 2%, highlighting its potential for diabetes research (Jastreboff et al., 2023).

References

1. Jakubowska et al., 2024
2. Folli et al., 2023
3. Doggrell, 2023
4. Conceição-Furber et al., 2022
5. Jastreboff et al., 2023
6. Rosenstock et al., 2023
7. van Bloemendaal et al., 2014
8. Samms et al., 2021
9. Urva et al., 2023